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Abstract 
Purpose: To evaluate the effect of Draba nemorosa extract (DNE) on oxidative stress and 
hemodynamics in rats with chronic congestive heart failure (CHF). 
Methods: Adriamycin was used to establish CHF in Sprague Dawley (SD) rat model. Six groups of SD 
rats were used in this study: control group, CHF group, captopril group (0.1 g/kg), as well as high-, 
medium- and low-dose DNE groups (5.2, 2.6 and 1.3 g/kg, respectively). Treatment for all groups lasted 
4 weeks. Blood pressure and heart index were measured. In addition, serum creatine kinase (CK), 
superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO) and nitric oxide synthase 
(NOS) were determined with enzyme-linked immunosorbent assay (ELISA) kits. 
Results: In the CHF group, arterial systolic pressure (SBP, 84.22 ± 16.23 mmHg); diastolic pressure 
(DBP, 77.36 ± 20.29 mmHg); mean arterial pressure (MAP, 78.45 ± 10.56 mmHg); heart rate (HR, 
357.18 ± 37.34 beats/min) and left ventricular systolic peak (LVSP, 102.34 ± 16.37 mmHg) were 
significantly decreased (p < 0.05) when compared with the control group. However, left ventricular end 
diastolic pressure (LVEDP, 23.38 ± 1.78 mmHg); heart index (2.74 ± 0.16 mg/g); serum CK (0.87 ± 0.15 
U/mL); MDA (19.34 ± 2.57 nmol/mL), NO (38.43 ± 3.32 umol/L) and NOS (42.65 ± 3.32 U/mL) were 
increased. Treatment with high-dose DNE significantly ameliorated hemodynamic function, and reduced 
MDA (9.13 ± 2.12 nmol/mL) and NO (22.37 ± 3.16 umol/L) levels (p < 0.05). High-dose DNE also led to 
significant decreases in CK (0.53 ± 0.35 U/mL) and NOS (24.27 ± 3.55U/mL) in the CHF rats (p < 0.05). 
Conclusion: DNE significantly improves hemodynamic function in CHF rats. Thus, it has a potential for 
development into a new drug for clinical treatment of CHF. 
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Chronic heart failure (CHF) is a consequence of 
cardiac disorder [1]. The incidence of heart 
failure (HF) in developed countries for people 
over 65 years old is about 1 % [2]. It has been 
shown that the morbidity from HF in ten 
provinces of China has reached 0.9 % [3]. 
However, it must be noted that the current 
prognosis of CHF is far from satisfactory, and 
therapeutic regimens are limited. To some 
extent, the situation is much worse for HF than 
cancer [4]. Furthermore, hospitalization burden 
and healthcare expenditures make HF a global 
health issue. 
 
The frequently adopted treatments for HF include 
angiotensin-converting enzyme (ACE) inhibitors, 
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β-adrenoceptor blockers, and digitalis [5-7]. 
Although the guidelines on CHF therapy have 
been updated by American Heart Association 
(AHA) and European Society of Cardiology 
(ESC) [2], HF remains a major cause death [8].  
Thus there is need to explore new therapeutic 
regimens for HF.  
 
The use of Traditional Chinese Medicine (TCM) 
for treatment of complex, multi-factorial diseases 
is gaining acceptance. It has been recognized 
that TCM effectively treats symptoms, reduce 
side effects and reverse resistance via targeting 
multiple pathways. TCMs such as Shengmai [9], 
Sini decoction [10], Shuanglong formula [11], and 
Huangqi injection have been reported to exhibit 
potential pharmacological activities against 
cardiovascular diseases [12]. Draba nemorosa 
stimulates blood circulation, thus eliminating 
blood stasis. It also contributes to replenishment 
of blood, reduces swelling and relieves pain 
[13,14]. So far, there are no reports in the 
literature on the use of Draba nemorosa for 
treating cardiovascular diseases. This study was 
aimed at investigating the effect of DNE on CHF 






Draba nemorosa was obtained from 
Pingdingshan City, Henan Province of China in 
May 2015, and identified by Professor Zhi He of 
Nanjing University, China. A voucher specimen 
(No. DNE 201505013) was kept at the College of 
Pharmacy, Jiangsu University of China, for future 
reference. An aqueous extract of Draba 
nemorosa was prepared and freeze-dried to 
obtain DNE at a yield of 50 % (2.0 g of Draba 




Healthy male SD rats were purchased from the 
Experimental Animal Center of Jiangxi Province 
(Certificate no. SYXK 2005-0004). They were 
kept in single cages in an atmosphere of 
temperature 20 ± 2 oC, and allowed free access 
to animal feed and clean drinking water. The 
experiment was approved by the Animal Care 
and Use Committee of the Second People's 
Hospital of Huai'an (approval ref no. 20110806). 
The study was carried out in accordance with 
Directive 2010/63/EU [15]. 
 
Modeling and treatment  
 
The experimental groups consisted of control 
group, adriamycin-treated CHF group, captopril 
group (0.1 g/kg), as well as high, middle and low-
dose (5.2, 2.6 and 1.3 g/kg, DNE groups, 
respectively, n = 10). Rats in the control group 
were administered an equivalent volume of 
saline in place of adriamycin hydrochloride (2 
mg/kg). Adriamycin rat model established via 
administration of the drug, once a week for 6 
weeks.  
 
At the 6th week, 2 rats were chosen and checked 
for heart failure. The adriamycin administration 
was extended for a further 4 weeks for rats that 
had not successfully developed heart failure 
(untreated rats). Drug administration began from 
the 7th week of the experiment and lasted for 4 
weeks. Except for the administration of saline to 
the control and adriamycin-induced CHF 
animals, DNE group received 1.3, 2.6 or 5.2 g/kg 
DNE once a day intra-gastrically, with 100 mg/kg 
captopril administrated to the captopril group 
only. 
 
Determination of cardiac function and 
hemodynamics 
 
Twenty-four h to the end of the experiment, the 
rats were anesthetized with 20% urethane 
solution (6 mL/kg). Then the animals were fixed 
in a spinal position. Ventricular cannula was used 
to separate the right common carotid artery using 
1.0 % heparin. Parameters concerning cardiac 
function were determined, and observation of 
pressure oscilloscope was performed. The 
advance was stopped when transformation of the 
wave shape was observed and the pulse 
pressure significantly was uplifted. The 
parameters recorded were LVSP, LVEDP, 
+dp/dtmax and -dp/dtmax. Mean values of the 
hemodynamic indices were obtained for 
calculations in 5 sections. Blood samples were 
thereafter collected from the abdominal aorta. 
Half of the blood samples were in sodium EDTA 
bottles, while the other half were without anti-
coagulant. All the samples were stored at -20 oC 
before analysis. 
 
Measurement of heart index  
 
Heart index (HI) was determined after cardiac 
function and hemodynamics measurements. The 
weight of the whole heart was measured, and the 
heart weight index was calculated as the ratio of 
whole heart weight (mg) to body weight (g). 
 
Determination of serum biochemical indices    
 
Serum CK, SOD, MDA, NO and NOS were 
determined using ELISA kits (Shenzhen Xin Bo 
Sheng Biological Technology Co., Ltd., 
Shenzhen, China) according to manufacturer’s  
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Statistical analysis  
 
Data are expressed as mean ± standard error of 
mean (SEM). Statistical Package SPSS 16.0 
(SPSS Inc, Illinois, Chicago, USA) was applied 
for data analysis using one-way analysis of 
variance (ANOVA) and Dunnett’s t-test. 




Effect of DNE on heart index 
 
There was a significant increase in HI in the 
model group when compared with the normal 
group (p < 0.05), which is an indication that 
myocardial hypertrophy was successfully 
established in the model group (Table 1). On the 
contrary, there was no significant variation in HI 
in the captopril and DNE groups. 
 
Table 1: Effect of DNE on heart index 
 
Group Dose (g/kg) HI (mg/g) 
Control - 2.14±0.22* 
Untreated - 2.94±0.15 
Captopril 0.1 2.41±0.23 
DNE-L 1.3 2.71±0.34 
DNE-M 2.6 2.54±0.29 
DNE-H 5.2 2.42±0.25 
 L, M and H represent low-, medium- and high-doses 
of DNE, respectively, (n = 10, *p < 0.05) 
 
Effect of DNE on hemodynamic parameters  
 
There were sharp decreases in SBP, DBP, MAP, 
LVSP, ± dp/dtmax and HR in the adriamycin-
treated CHF group, when compared with control 
(p < 0.05). Significant increases in LVEDP (p < 
0.01) were observed in the model group relative 
to the control group, but DNE (high dose) was 
able to bring about a significant reduction in this 
parameter. Moreover, DNE led to significant 
improvement in vasomotoricity and left 
ventricular function in adriamycin-treated CHF 
rats (p < 0.05), while captopril exhibited very little 
effect (Tables 2 and 3). 
 
Effect of DNE on serum biochemical indices  
 
There were significant increases (p < 0.01) in 
blood levels of CK, NOS, MDA, and NO levels, 
and sharp decreases (p < 0.01) in activity of 
SOD in blood of rats in the CHF group, when 
compared with control. However, captopril 
administration brought about significant 
reductions in CHF-induced increases in blood 
levels of CK, NOS, MDA, and NO (p < 0.01), 
while DNE had no significant effect on SOD 




In this study, cardiac function was assessed by 
various hemodynamic parameters. The results 
obtained suggest that diastolic function and 
contraction could be improved by DNE. 
 
The left ventricular function was appreciably 
improved without affecting heart rate. It appeared 
that DNE exhibited higher pharmacological 
activity than captopril. Heart failure can be 
induced by oxidative stress [16], since reactive 
 
         Table 2: Effect of DNE on hemodynamic indices 
 
Group Dose (g/kg) SBP (mmHg) DBP (mmHg) MAP (mmHg) HR (beats/min) 
Control — 125.45±13.37* 113.43±16.41* 105.28±13.35* 428.24±31.38* 
Untreated — 84.22±16.23 77.36±20.29 78.45±10.56 357.18±37.34 
Captopril 0.1 117.25±26.58 93.25±33.47 98.32±25.31 409.33±48.26 
DNE-L 1.3 91.43±20.23 82.42±26.35 82.26±16.26 379.39±34.31 
DNE-M 2.6 110.34±17.24* 97.27±18.57 94.31±15.42 389.36±28.58 
DNE-H 5.2 123.32±13.48** 105.32±21.32** 112.34±12.76** 417.28±38.24* 
       L, M and H represent low-, medium- and high-doses of DNE, respectively, (n = 10, *p < 0.05, **p < 0.05)  
 
Table 3: Effect of DNE on hemodynamic indices 
 
Group Dose (g/kg) 
LVSP 
(mmHg) LVEDP (mmHg) +dp/dtmax -dp/dtmax 
Control — 153.41±12.86* 8.43±1.56** 3745.26±415.53* 3765.35±437.53* 
Untreated — 102.34±16.37 23.38±1.78 2154.16±643.56 2367.34±653.23 
Captopril 0.1 115.27±31.48 15.27±2.36 3536.43±818.24 3452.21±706.34 
DNE-L 1.3 112.36±19.33 16.34±2.08 2435.32±557.34 2543.45±626.75 
DNE-M 2.6 125.17±15.35* 14.28±2.57 3213.25±487.76* 3324.25±532.25* 
DNE-H 5.2 138.25±16.22* 11.17±2.33* 3594.31±512.26* 3654.31±515.28* 
L, M and H represent low-, medium- and high-doses of DNE, respectively, (n = 10, *p < 0.05, **p < 0.05) 
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Table 4: Effect of DNE on some serum biochemical indices 
 
Group Dose (g/kg) CK (U/mL) SOD (U/mgprot) MDA (nmol/mL) NO (umol/L) NOS (U/mL) 
Control - 0.39±0.13** 96.43±7.26** 6.48±1.65** 18.24±1.84** 23.36±3.16** 
Model - 0.87±0.15 68.26±3.63 19.34±2.57 38.43±3.32 42.65±3.32 
Captopril 0.1 0.43±0.11** 83.15±8.32 9.27±1.87** 21.32±3.41** 33.48±2.56 
DNE-L 1.3 0.81±0.21 70.57±7.31 14.22±2.53 33.13±4.13 39.46±3.23 
DNE-M 2.6 0.67±0.25 72.34±7.24 12.34±2.28 26.27±3.53* 35.32±3.64 
DNE-H 5.2 0.53±0.35 77.42±6.31 9.13±2.12** 22.37±3.16** 24.27±3.55** 
L, M and H represent low-, medium- and high-doses of DNE, respectively, (n = 10, *p < 0.05, **p < 0.05) 
 
oxygen species and nitric oxide are involved in 
the process. Free radicals induce lipid 
peroxidation which damages cell membranes 
and accelerates cell apoptosis. Physiological 
antioxidants neutralize these free radicals, and 
NO is a physiological vasodilator. However, high 
levels of NO can lead to free radical formation 
and result in serious neurotoxicity, thus 
damaging the tissues. The synthesis of NO 
requires NOS [17]. In this study, DNE 
significantly reversed the CHF-induced increases 
in MDA and NO levels, and also decreased CK 
and NOS activities. Thus DNE reduced the 
oxidative stress state brought about by CHF. 
However, DNE had no significant effect on the 
activity of SOD, suggesting the effect of DNE 




The findings of this study has demonstrated that 
DNE appreciably ameliorates chronic congestive 
heart failure, most probably by mitigation of 
oxidative stress, and the recovery of left 
ventricular function. Thus, DNE may be a 
potential source of new drug(s) for treating 
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